- 로타바이러스 백신은 접종 시기가 정해져 있습니다.2
- 로타텍 2, 4, 6개월(예시)로 3회 접종합니다.†
† 1차 투여는 생후 6-12주에 하고, 이후 각 투여간 4주 내지 10주의 간격을 두고 추가 투여합니다.
3차 투여는 생후 32주를 넘어서는 안됩니다.
‡각 연령에서 백신 효과(Vaccine effectiveness)는 다음과 같았습니다.
1세 91%(95% CI : 78-96), 2세 82%(95% CI : 69-89), 3세 88%(95% CI : 78-93), 4세 76%(95% CI : 51-88), 5세 60%(95% CI : 16-81), 6-7세 69%(95% CI : 43-84)
- Payne DC, Selvarangan R, Azimi PH, et al. Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children,
2012-2013. Clin Infect Dis. 2015;61(12):1792-9.
- Using a multicenter, active surveillance network from 2 rotavirus seasons (2012 and 2013), this study assessed the vaccine effectiveness of RV5 (RotaTeq) and RV1 rotavirus vaccines in preventing rotavirus gastroenteritis hospitalizations and emergency department (ED) visits for numerous demographic and secular strata. Children were enrolled if they were hospitalized or visiting the ED with acute gastroenteritis (AGE) for the 2012 and 2013 seasons at 7 medical institutions. Stool specimens were tested for rotavirus by enzyme immunoassay and genotyped, and rotavirus vaccination histories were compared for rotavirus-positive cases and rotavirus-negative AGE controls. The vaccine effectiveness (VE) was calculated for preventing rotavirus associated hospitalizations and ED visits for each vaccine, stratified by vaccine dose, season, clinical setting, age, predominant genotype, and ethnicity